Ann Arbor-based Strata Oncology Inc. is expanding the clinical trial of its Sentinel early cancer treatment with the addition of University of Michigan’s Rogel Cancer Center and the Lehigh Valley Topper Cancer Institute (LVTCI) in Pennsylvania.
The trial is a test of the Strata SentinalMRD, a minimal residual disease test that has the potential to shift the paradigm of cancer care, bringing the use of biomarker-matched precision therapies to earlier stages of the disease, the company says.
“By helping identify cancer recurrences as early as possible, StrataMRD has tremendous potential to change how we care for patients after initial cancer treatment,” says Dr. Todd Morgan, a research professor at the University of Michigan Medical School and chief of urologic oncology at University of Michigan Health.
“We are pleased to partner with Strata Oncology to not only study the impact of StrataMRD on our patient population, but to work together to establish the workflows and data management systems necessary to implement precision oncology across a health system at scale.”
Strata’s co-founder and CEO Dan Rhodes says the trial is a key piece of the company’s strategy to developing integrated solutions to enable smarter and earlier cancer treatment. He adds that partners like U-M and the Lehigh Valley Topper Cancer Institute are vital to “not only collect clinical validation and utility data, but also to learn together to create the sustainable, scalable systems necessary to deliver the best possible treatment to every patient with cancer.”
“At Lehigh Valley Topper Cancer Institute, we are continuously working to improve cancer care, including partnering with innovators to bring the latest technology to the patients we serve,” says Dr. Suresh Nair, physician in chief of the LVTCI. “With the Strata Sentinel trial, we aim to demonstrate the utility of detecting recurrence as soon as possible using the ctDNA-based SentinelMRD test. We will also evaluate the clinical benefit of treating patients with micrometastatic disease, including with biomarker-matched therapies chosen based on the extended treatment selection data provided by Strata Oncology platform.”
Patients interested in learning more about the Strata Sentinel trial can visit here.
